27 Aug 25
Navigating SME Status in the EU
Small and medium enterprise (SME) designation in the EU can yield cost savings, strategic guidance from Health Authorities and enhanced credibility.
SME status from the European Medicines Agency (EMA) delivers benefits such as fee exemptions and reductions for pre- and post-authorisation regulatory procedures, including scientific advice, inspections, and pharmacovigilance, as well as assistance with translation of documents into all EU languages at the time of Marketing Authorisation Application (MAA). Beyond cost savings, SMEs can leverage specific EMA guidance documents and interactions, plus can gain visibility via the EMA’s SME register – helping build networks and partnerships.
The incentives are designed not just to ease financial burden, but to accelerate the drug development journey from concept to patient.
To achieve SME status, companies must submit documentation detailing employee accounts and financial details – typically validated by an external accountant.
Did you know that you do not need to be located in the EU to benefit from SME status? tranScrip can guide you through the SME application process, allowing you to benefit indirectly from our SME status.
Understanding Orphan Drug Designation in the EU
Orphan Drug Designation (ODD) aims to encourage the development of medicines that target rare conditions that are life‑threatening or chronically debilitating and have significant unmet medical need. In the EU, orphan conditions are defined as those that affect less than 5 per 10,000 people.
In the EU, authorised orphan medicines benefit from ten years of protection against competing products with the same indications once they are approved. This period of protection is extended by two years for medicines that have complied with an agreed paediatric investigation plan, granted at the time of review of the orphan medicine designation. Other incentives include reduced fees for Protocol Assistance and automatic eligibility for the Centralised Procedure.
tranScrip has extensive experience of applying for EU SME status and ODD and can help you navigate the ever-changing regulatory environment. We are ready to support your applications for SME status or ODD and help you to bring effective medicines to patients across the EU and beyond.
Ready to Maximise EU Incentives and Accelerate Your Drug Development?
Whether you’re seeking SME status, Orphan Drug Designation, or both – tranScrip is here to guide you every step of the way. Our proven regulatory expertise and hands-on support can help you unlock critical cost savings, fast-track your development, and bring life-changing treatments to patients sooner.
Schedule a compliment call to explore how we can support your SME or ODD application: Contact us
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.